Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zevalin followed by Rituxan maintenance in low grade NHL
NCT00168727Phase 4Completed
- Sponsor
- Biogen
- Start
- Jun 2003
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ibritumomab tiuxetan in non-Hodgkin lymphoma (NHL), sponsored by Biogen. Primary endpoints: Overall Response Rate, Event-Free Survival and 3 more. Started Jun 2003; status: completed.
02
Drugs
ibritumomab tiuxetan
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00168727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00168727.